Collegium Pharmaceutical (NASDAQ:COLL) Reaches New 1-Year High – Here’s What Happened

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) hit a new 52-week high on Monday . The company traded as high as $49.48 and last traded at $48.70, with a volume of 217 shares trading hands. The stock had previously closed at $48.63.

Analyst Ratings Changes

A number of brokerages recently issued reports on COLL. Needham & Company LLC reiterated a “buy” rating and issued a $46.00 target price on shares of Collegium Pharmaceutical in a research report on Tuesday, October 28th. Truist Financial increased their price objective on shares of Collegium Pharmaceutical from $45.00 to $48.00 and gave the company a “buy” rating in a report on Friday, November 7th. Barclays assumed coverage on shares of Collegium Pharmaceutical in a research note on Monday, December 8th. They set an “overweight” rating and a $58.00 price objective on the stock. HC Wainwright upped their target price on Collegium Pharmaceutical from $44.00 to $46.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Finally, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Collegium Pharmaceutical in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, Collegium Pharmaceutical presently has an average rating of “Buy” and an average price target of $47.00.

Collegium Pharmaceutical Price Performance

The firm has a market capitalization of $1.54 billion, a P/E ratio of 30.25 and a beta of 0.61. The business’s fifty day moving average is $41.31 and its 200 day moving average is $36.30. The company has a current ratio of 1.36, a quick ratio of 1.27 and a debt-to-equity ratio of 2.71.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Wednesday, September 4th. The specialty pharmaceutical company reported $1.26 earnings per share for the quarter. The firm had revenue of $135.55 million during the quarter. Collegium Pharmaceutical had a net margin of 7.72% and a return on equity of 102.03%. As a group, analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current year.

Insider Activity

In other Collegium Pharmaceutical news, Director Rita J. Balice-Gordon sold 3,650 shares of the company’s stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $47.03, for a total transaction of $171,659.50. Following the completion of the sale, the director directly owned 52,629 shares of the company’s stock, valued at approximately $2,475,141.87. This represents a 6.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Scott Dreyer sold 17,600 shares of the firm’s stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $48.17, for a total transaction of $847,792.00. Following the completion of the transaction, the executive vice president owned 103,613 shares of the company’s stock, valued at approximately $4,991,038.21. The trade was a 14.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 51,250 shares of company stock valued at $2,235,352 over the last three months. Insiders own 2.51% of the company’s stock.

Institutional Investors Weigh In On Collegium Pharmaceutical

Several hedge funds have recently made changes to their positions in the company. Amundi raised its stake in Collegium Pharmaceutical by 302.1% during the 1st quarter. Amundi now owns 62,592 shares of the specialty pharmaceutical company’s stock valued at $1,816,000 after purchasing an additional 47,024 shares during the period. Bank of New York Mellon Corp boosted its position in shares of Collegium Pharmaceutical by 3.1% in the second quarter. Bank of New York Mellon Corp now owns 249,875 shares of the specialty pharmaceutical company’s stock worth $7,389,000 after buying an additional 7,614 shares during the period. Fortis Capital Advisors LLC purchased a new position in shares of Collegium Pharmaceutical during the first quarter valued at $408,000. Rhumbline Advisers raised its position in Collegium Pharmaceutical by 3.1% during the first quarter. Rhumbline Advisers now owns 111,628 shares of the specialty pharmaceutical company’s stock valued at $3,332,000 after buying an additional 3,400 shares during the period. Finally, Nuveen LLC acquired a new position in Collegium Pharmaceutical during the first quarter valued at $2,674,000.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.